The more I read this article, the more I felt like I was holding the elevator pitch of my startup iNutri Italia 🍊
I quote the part that struck me the most with a 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹 𝗿𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗼𝗻 at the end:
"𝘕𝘦𝘭 2022, 𝘴𝘦𝘤𝘰𝘯𝘥𝘰 𝘪 𝘥𝘢𝘵𝘪 𝘥𝘦𝘭𝘭'𝘖𝘮𝘴, 2,5 𝘮𝘪𝘭𝘪𝘢𝘳𝘥𝘪 𝘥𝘪 𝘢𝘥𝘶𝘭𝘵𝘪 𝘥𝘪 𝘦𝘵à 𝘱𝘢𝘳𝘪 𝘰 𝘴𝘶𝘱𝘦𝘳𝘪𝘰𝘳𝘦 𝘢 18 𝘢𝘯𝘯𝘪 𝘦𝘳𝘢𝘯𝘰 𝘪𝘯 𝘴𝘰𝘷𝘳𝘢𝘱𝘱𝘦𝘴𝘰, 𝘪𝘯𝘤𝘭𝘶𝘴𝘪 𝘰𝘭𝘵𝘳𝘦 890 𝘮𝘪𝘭𝘪𝘰𝘯𝘪 𝘥𝘪 𝘢𝘥𝘶𝘭𝘵𝘪 𝘤𝘩𝘦 𝘤𝘰𝘯𝘷𝘪𝘷𝘦𝘷𝘢𝘯𝘰 𝘤𝘰𝘯 𝘭'𝘰𝘣𝘦𝘴𝘪𝘵à. 𝘜𝘯'𝘪𝘮𝘱𝘦𝘯𝘯𝘢𝘵𝘢 𝘳𝘪𝘴𝘱𝘦𝘵𝘵𝘰 𝘢𝘭 1990, 𝘲𝘶𝘢𝘯𝘥𝘰 𝘪𝘭 25% 𝘥𝘦𝘨𝘭𝘪 𝘢𝘥𝘶𝘭𝘵𝘪 𝘥𝘪 𝘦𝘵à 𝘱𝘢𝘳𝘪 𝘰 𝘴𝘶𝘱𝘦𝘳𝘪𝘰𝘳𝘦 𝘢 18 𝘢𝘯𝘯𝘪 𝘦𝘳𝘢 𝘪𝘯 𝘴𝘰𝘷𝘳𝘢𝘱𝘱𝘦𝘴𝘰, 𝘤𝘩𝘦 𝘯𝘰𝘯 𝘪𝘯𝘵𝘦𝘯𝘥𝘦 𝘧𝘦𝘳𝘮𝘢𝘳𝘴𝘪. 𝘐𝘯𝘧𝘢𝘵𝘵𝘪, 𝘣𝘢𝘴𝘢𝘯𝘥𝘰𝘴𝘪 𝘴𝘶𝘭𝘭𝘦 𝘵𝘦𝘯𝘥𝘦𝘯𝘻𝘦 𝘢𝘵𝘵𝘶𝘢𝘭𝘪, 𝘶𝘯 𝘯𝘶𝘰𝘷𝘰 𝘳𝘦𝘱𝘰𝘳𝘵 𝘥𝘦𝘭𝘭𝘢 𝘞𝘰𝘳𝘭𝘥 𝘖𝘣𝘦𝘴𝘪𝘵𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘷𝘦𝘥𝘦 𝘤𝘩𝘦 𝘦𝘯𝘵𝘳𝘰 𝘪𝘭 2035 𝘪𝘭 51% 𝘥𝘦𝘭𝘭𝘢 𝘱𝘰𝘱𝘰𝘭𝘢𝘻𝘪𝘰𝘯𝘦 𝘮𝘰𝘯𝘥𝘪𝘢𝘭𝘦 𝘴𝘢𝘳à 𝘪𝘯 𝘤𝘰𝘯𝘥𝘪𝘻𝘪𝘰𝘯𝘦 𝘥𝘪 𝘴𝘰𝘷𝘳𝘢𝘱𝘱𝘦𝘴𝘰 𝘰 𝘰𝘣𝘦𝘴𝘪𝘵à. 𝘕𝘦𝘭 𝘥𝘦𝘵𝘵𝘢𝘨𝘭𝘪𝘰, 𝘶𝘯𝘢 𝘱𝘦𝘳𝘴𝘰𝘯𝘢 𝘴𝘶 𝘲𝘶𝘢𝘵𝘵𝘳𝘰 (𝘲𝘶𝘢𝘴𝘪 2 𝘮𝘪𝘭𝘪𝘢𝘳𝘥𝘪) 𝘴𝘰𝘧𝘧𝘳𝘪𝘳à 𝘥𝘪 𝘰𝘣𝘦𝘴𝘪𝘵à."
But does this not 𝘀𝗰𝗮𝗿𝗲 you?
What is most important to consider are the many 𝗰𝗼𝗻𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲𝘀 that such a condition can bring, many 𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝗶𝗲𝘀 can result from it and I am not going to list them all, just do a simple search on the internet to get an idea.
Pathologies that affect the 𝗽𝗵𝘆𝘀𝗶𝗰𝗮𝗹 and 𝗽𝘀𝘆𝗰𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 appearance of those affected, in addition to being an increasingly competitive society that lives online it is easy to fall into the limbo of comparison with “perfect” and modeled models that lead to a vicious circle.
I am not talking about DCA and associated disorders because it is not my area of expertise, but I would like to point out how these situations often start at a very low age, even the age of 𝘆𝗼𝘂𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 with nutrition-related disorders has dropped.
According to the 𝘍𝘪𝘳𝘴𝘵 𝘖𝘣𝘦𝘴𝘪𝘵𝘺 𝘈𝘵𝘭𝘢𝘴 - 𝘞𝘰𝘳𝘭𝘥 𝘖𝘣𝘦𝘴𝘪𝘵𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘵𝘪𝘰𝘯 young people of pediatric age (3-14 years) suffering from 𝗲𝗮𝘁𝗶𝗻𝗴 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 in Italy are about 35% and it is expected to reach 45.1% in 2030.
It is good to be aware of this situation and to start as soon as possible with more effective and interconnected systems to 𝗽𝗿𝗲𝘃𝗲𝗻𝘁, 𝗺𝗲𝗮𝘀𝘂𝗿𝗲, 𝗮𝗻𝗱 𝗰𝗼𝗿𝗿𝗲𝗰𝘁 these issues so that this trend is stopped and reversed.
#pharma #nutrition #disorders #pathologies #startup #trend #healthcare #forbes #nutritiondisorders #dca #𝗽𝘀𝘆𝗰𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹
L’intelligenza artificiale non è l’unico trend che sta trainando il mercato azionario e conquistando l’attenzione mediatica e delle principali società mondiali. Guardando ai numeri, alle sue implicazioni e soprattutto alla gigantesca platea che coinvolge si sta sempre più affermando un altro trend, già ampiamente noto e ‘più tradizionale’: la lotta all’obesità.
Una ricerca spasmodica che sta permettendo ad alcune delle principali case farmaceutiche di aumentare sensibilmente i propri introiti economici, grazie alla scoperta (anche causale) di alcuni farmaci, inizialmente indicati per la cura del diabete, ‘dimagranti’, diventati in pochissimi mesi quasi introvabili a causa dell’eccessiva richiesta e della poca offerta.
Entro il 2030 il mercato dei farmaci anti-obesità varrà 100 miliardi. E sarà trainato da Eli Lily e Novo Nordisk
forbes.it